FogPharma
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $323M
Overview
Developing Helicon polypeptides to drugg intracellular targets with antibody-like precision.
Oncology
Technology Platform
The Helicon platform designs and optimizes cell-penetrating mini-proteins (polypeptides) to inhibit intracellular protein-protein interactions with high specificity.
Funding History
2Total raised:$323M
Series E$145M
Series C$178M
Opportunities
Validating its platform could open up a vast new target class across multiple therapeutic areas beyond oncology.
Risk Factors
Clinical proof-of-concept for a first-in-class modality carries high technical and biological risk.
Competitive Landscape
Competes with other companies targeting undruggable targets (e.g., Kymera, Nurix with degraders) but has a distinct modality focused on direct inhibition via cell penetration.